Dupilumab-associated head and neck dermatitis (HND) is a rare and often underrecognized condition, especially in patients with skin of color. It can vary from subtle to severe presentations, with violaceous hues and seborrheic distribution after dupilumab initiation. Early recognition and management are crucial to prevent treatment discontinuation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865336 | PMC |
| http://dx.doi.org/10.1002/ccr3.70271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recognizing Dupilumab-Associated Head and Neck Dermatitis in Skin of Color: A Case Series.
Clin Case Rep
March 2025
Department of Dermatology School of Medicine, Virginia Commonwealth University Richmond Virginia USA.
Dupilumab-associated head and neck dermatitis (HND) is a rare and often underrecognized condition, especially in patients with skin of color. It can vary from subtle to severe presentations, with violaceous hues and seborrheic distribution after dupilumab initiation. Early recognition and management are crucial to prevent treatment discontinuation.
View Article and Find Full Text PDFDupilumab-Associated Ocular Surface Disease in Pediatric Atopic Dermatitis: A Single-Center Asian Experience.
Pediatr Dermatol
November 2024
Department of Dermatology, KK Women's and Children's Hospital, Singapore, Singapore.
Article Synopsis
- Atopic dermatitis (AD) is a common chronic skin condition in children, and dupilumab is the first approved biologic treatment for moderate-to-severe cases; however, it can lead to ocular surface disease (DAOSD).
- A study was conducted on Asian pediatric patients who developed DAOSD while being treated with dupilumab, analyzing their demographic information, eye symptoms, and treatment outcomes.
- Among 216 patients, 16 (7.4%) experienced DAOSD, mainly presenting with symptoms like eye redness and conjunctivitis; however, the severity in children seemed lower than in adults, and prophylactic measures can help minimize complications.
Real-world efficacy and safety of dupilumab for paediatric atopic dermatitis: a multicentre retrospective study.
Clin Exp Dermatol
January 2025
Pediatric Dermatology Unit, Department of Dermatology, Sheba Medical Center, Israel.
Background: Real-world data regarding the use of dupilumab in children with atopic dermatitis (AD) are limited.
Objectives: To evaluate the real-world efficacy of dupilumab in children with moderate-to-severe AD over an extended follow-up period.
Methods: This was a retrospective study of patients (≤ 18 years) with moderate-to-severe AD treated with dupilumab in four Israeli tertiary centres.
Fungal Head and Neck Dermatitis: Current Understanding and Management.
Clin Rev Allergy Immunol
June 2024
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
Article Synopsis
- Head and neck dermatitis (HND) is a severe form of atopic dermatitis that primarily affects seborrheic areas and significantly impacts patients’ quality of life, with treatment being complicated by the ineffectiveness of usual topical therapies and the potential for dupilumab-associated dermatitis (DAHND).
- Research indicates that fungi, particularly Malassezia species, play a crucial role in HND development, as they activate the immune system and cause inflammation via specific immune pathways.
- While antifungals show promise in treating HND, particularly in oral form, the long-term effects are uncertain; new therapies like Janus kinase inhibitors and OX40 inhibitors are being explored, and factors like host microbiome variations could lead to more
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice.
J Clin Med
June 2024
Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition with a substantial impact on patients, particularly due to ocular involvement known as atopic keratoconjunctivitis (AKC). Current therapeutic approaches, such as dupilumab, often lead to conjunctivitis, prompting exploration of alternative treatments like upadacitinib. We collected dermatological and ophthalmological prospective clinical evaluations of six adults with moderate-to-severe AD, undergoing treatment with upadacitinib after discontinuation of dupilumab due to the onset of AKC during therapy and the worsening of dermatitis in particular in the head and neck region.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!